KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics (PVLA) Current Assets (2016 - 2026)

Palvella Therapeutics has reported Current Assets over the past 10 years, most recently at $73.4 million for Q4 2022.

  • Quarterly Current Assets fell 42.47% to $73.4 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $73.4 million through Dec 2022, down 42.47% year-over-year, with the annual reading at $73.4 million for FY2022, 42.47% down from the prior year.
  • Current Assets was $73.4 million for Q4 2022 at Palvella Therapeutics, down from $78.6 million in the prior quarter.
  • Over five years, Current Assets peaked at $166.1 million in Q1 2018 and troughed at $73.4 million in Q4 2022.
  • The 5-year median for Current Assets is $111.6 million (2019), against an average of $112.2 million.
  • Year-over-year, Current Assets skyrocketed 182.66% in 2018 and then plummeted 42.93% in 2022.
  • A 5-year view of Current Assets shows it stood at $135.4 million in 2018, then fell by 15.05% to $115.0 million in 2019, then tumbled by 34.16% to $75.7 million in 2020, then surged by 68.55% to $127.6 million in 2021, then plummeted by 42.47% to $73.4 million in 2022.
  • Per Business Quant, the three most recent readings for PVLA's Current Assets are $73.4 million (Q4 2022), $78.6 million (Q3 2022), and $90.9 million (Q2 2022).